Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 7/20 | 0.44 |
| ▸ | JAK1 | P23458 | 7/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.39 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4447061 | 0.86 | JAK2 (0.47) | JAK2JAK1CTSLCTSBCTSS | |
| SCHEMBL5671931 | 0.83 | OPRD1 (0.47) | JAK2JAK1CTSLCTSBCTSS | |
| SCHEMBL28597842 | 0.82 | SMN1; SMN2 (0.43) | JAK2JAK1GPR119STS | |
| SCHEMBL850214 | 0.72 | CTSK (0.37) | JAK2JAK1GPR119 | |
| SCHEMBL26982022 | 0.72 | ALDH1A1 (0.41) | JAK2JAK1GPR119STS | |
| SCHEMBL21083118 | 0.72 | JAK1 (0.49) | JAK2JAK1GPR119STS | |
| SCHEMBL22989504 | 0.72 | JAK1 (0.41) | JAK2JAK1 | |
| SCHEMBL13607137 | 0.71 | JAK2 (0.48) | JAK2JAK1GPR119STSOPRD1 | |
| SCHEMBL4446810 | 0.71 | JAK2 (0.48) | JAK2JAK1GPR119STSOPRD1 | |
| SCHEMBL31437378 | 0.71 | JAK2 (0.45) | JAK2JAK1GPR119STSOPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632840-B2 | Quinazoline compounds for the treatment of hyperproliferative disorders | ASTRAZENECA AB (SE) | 2009-12-15 | — | — | US | disclosed |
| EP-1713781-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| US-20070293490-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2007-12-20 | — | — | US | disclosed |
| EP-1713781-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005075439-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293490-A1 | Quinazoline Derivatives | CCNA1, CCND3, CCND2 | JAK2 839/4885JAK1 325/4885CTSL 1808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.